About Exelead
Exelead is a company based in Indianapolis (United States) founded in 2016 was acquired by Merck in January 2022. Exelead offers products and services including Lipid Nanoparticle CDMO and mRNA Development and Manufacturing. Exelead operates in a competitive market with competitors including Exela Pharma, Gland Pharma, August Bioservices, ApiJect and Vetter Pharma, among others.
- Headquarter Indianapolis, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Exelead
Exelead offers a comprehensive portfolio of products and services, including Lipid Nanoparticle CDMO and mRNA Development and Manufacturing.
Service for developing and manufacturing lipid nanoparticles for drug delivery
Provides synthesis, purification, and formulation for mRNA products
People of Exelead
Unlock access to complete
Unlock access to complete
Funding Insights of Exelead
Detailed funding history for Exelead
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Exelead
Exelead has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Merck is engaged in science and technology solutions globally.
|
Locked | Locked | Locked |
Investor details for Exelead
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exelead
Investment portfolio details for Exelead
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Exelead
Detailed financials for Exelead
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exelead Comparisons
Peer comparison for Exelead
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exelead
Exelead operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Exela Pharma, Gland Pharma, August Bioservices, ApiJect and Vetter Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sterile injectable pharmaceuticals are manufactured alongside CDMO services.
|
|
| Locked | Locked | Locked |
Generic injectable drugs are manufactured across therapeutic segments.
|
|
| Locked | Locked | Locked |
Diversified research services for clinical solutions are offered.
|
|
| Locked | Locked | Locked |
Medicine injectors are manufactured by ApiJect for medical applications.
|
|
| Locked | Locked | Locked |
CDMO specializing in aseptically prefilled syringe systems, cartridges and vials.
|
|
| Locked | Locked | Locked |
Injectable drug products are manufactured by this biopharma CDMO.
|
Detailed competitors of Exelead
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exelead
Complete news archive for Exelead
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exelead
Exelead was founded in 2016.
Exelead is headquartered in Indianapolis, United States. It is registered at Indianapolis, Indiana, United States.
Exelead, a wholly owned subsidiary of Leadiant Biosciences, is a contract manufacturer of liquid injectables and specializes in the development and manufacturing of complex liposomal and pegylated formulations. The company has capabilities to manufacture for both clinical and commercial applications. Their clientele includes companies ranging from small, venture startups to medium size companies. The company is capable of handling small batches and formulations which are meant for rare disease and small populations. Their clientele includes Teva, Shire (Exelead is the CMO for Oncaspar), Horizon Pharma and Aradigm. The company also has an in-house portfolio which includes Adagen (a pegademase bovine injection), DepoCyt (cytarabine liposome injection), and Abelcet (amphotericin B lipid complex injection).
Exelead's top competitors include Exela Pharma, Gland Pharma and Luoxin Pharmaceutical Group.
Exelead offers Lipid Nanoparticle CDMO and mRNA Development and Manufacturing.
Exelead has 1 investor. Key investors include Merck.